Study of ABBV-932 for generalized anxiety disorder
Part of Mental health clinical trials.
This trial tests an oral medicine called ABBV-932 when added to current antidepressant therapy for people with generalized anxiety disorder (GAD) who still have symptoms. It aims to see if the combination can improve anxiety and reduce side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with generalized anxiety disorder (GAD) as defined by a doctor using standard criteria.
- You are currently taking an antidepressant for GAD but it hasn't worked well enough after at least 8 weeks at the right dose.
- Your anxiety is at least moderate, as shown by a score of 20 or higher on a standard anxiety scale.
- You do not have severe depression (a score of 20 or more on a depression scale).
- You have not been diagnosed with major depression or had it get worse in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a psilocybin oral solution in adults with generalized anxiety disorder (GAD). It aims to see if the drug is safe, tolerable, and helpful for reducing anxiety symptoms.
This study aims to better understand generalized anxiety disorder by following a group of people over time. You won't receive a new treatment, but you will help researchers learn more about the condition, which may lead to better care in the future.
This trial tests if adding cannabidiol (CBD) to a learning-based approach helps manage generalized anxiety disorder (GAD). It involves brain scans and taking CBD daily.
This study tests an investigational oral medication (ITI-1284) for people with moderate to severe generalized anxiety disorder (GAD) who haven't found enough relief from at least two standard medications. The goal is to see if this new drug helps reduce anxiety symptoms.
This trial tests a new medication called RE104 for people with generalized anxiety disorder (GAD). The goal is to see if it helps reduce anxiety symptoms safely.
This trial tests an investigational medication to see if it can reduce anxiety symptoms in adults with generalized anxiety disorder. Participants will receive the study drug and be monitored for safety and effectiveness.
Hear when a new Generalized Anxiety Disorder (GAD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.